Toolkit NCSL Prescription Drug Policy Resource Center

States passed a steady stream of bills in 2022 to address educational disruptions caused by the COVID-19 pandemic and K-12 students’ continued reports of elevated levels of stress, depression and anxiety.

To reduce knowledge gaps that result from the underrepresentation of people of color and LGBTQ individuals in clinical trials of new drugs, state and federal lawmakers along with industry groups are working to make drug trials more diverse.

Lawmakers are turning to approaches that span multiple policy areas to help older adults face the unique social, physical and economic challenges associated with aging.